PMA device
FoundationOne Liquid CDx
Foundation Medicine, Inc. · Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP, Class III) · First FDA decision Aug 26, 2020, newest May 27, 2026Cancer detection and genomic testing
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
18
PMA pathway
Device trials
0
Naming "FoundationOne Liquid CDx"
MAUDE reports
0
Brand "FoundationOne Liquid CDx", since 2015
PubMed studies
80
Mentioning "FoundationOne Liquid CDx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing FoundationOne Liquid CDx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 18 decisions filed under this name.
- FoundationOne Liquid CDxPMA supplement
P190032-S029 · Decided May 27, 2026 · 490 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- FoundationOne Liquid CDxPMA supplement
P200016-S002 · Decided Mar 8, 2023 · 180 days after receipt · Normal 180 Day Track No User Fee
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- FoundationOne Liquid CDx (F1 Liquid CDx)PMA supplement
P200006-S004 · Decided Mar 8, 2023 · 180 days after receipt · Normal 180 Day Track No User Fee
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: P190032-S023, P190032-S017, P190032-S015, P190032-S014, P190032-S011, P190032-S010, P190032-S009, P190032-S005, P190032-S004, P190032-S003, P190032-S001, P190032
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40210Palmetto GBAUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40278WPS Insurance CorporationUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40226CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40222Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40278WPS Insurance CorporationUpdated Sep 15, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40222Noridian Healthcare Solutions, LLCUpdated Aug 22, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40226CGS Administrators, LLCUpdated Aug 21, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40210Palmetto GBAUpdated Aug 18, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "FoundationOne Liquid CDx", any status and sponsor, newest update first.
No registered device study names "FoundationOne Liquid CDx".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "FoundationOne Liquid CDx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PQP
14 reports: 11 malfunction, 2 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Hamilton Microlab STAR Liquid Handler; Protocol Configuration Tool (PCT) v2.0.0. Used to conduct F1CDx and F1LCDx.Open, Classified
Z-2951-2026 · Started Jun 10, 2026 · Posted by FDA Aug 14, 2026
Reason given: Software issue that can cause an increase in spontaneous software closures.
Cause as FDA categorized it: Software design · Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
- FoundationOne Liquid CDx (F1LCDx), TECH-0009 version 6.0Open, Classified
Z-0578-2026 · Started Nov 8, 2022 · Posted by FDA Nov 21, 2025
Reason given: Reports were sent to customers without the companion diagnostic (CDx) Claims Page. Claims pages were distributed via amended reports within 7 days of the issue occurrence.
Cause as FDA categorized it: Under Investigation by firm · Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
Published research
The most relevant PubMed records for "FoundationOne Liquid CDx"[tiab]. The summary above synthesizes these.
- Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer.
Yaeger R, Martini JF, Pasquina L, et al. · Cancer Res Commun · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R, Li M, Hughes J, et al. · PLoS One · 2020Research Support, Non-U.S. Gov't, Validation Study
- Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis.
Isla D, Álvarez R, Arnal M, et al. · J Med Econ · 2024
- Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
Matsubara N, de Bono J, Olmos D, et al. · Clin Cancer Res · 2023Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- High-Specificity Detection of UV Mutational Signatures in Circulating Tumor DNA for Diagnostic Classification of Cutaneous and Unknown Primary Tumors Using FoundationOne Liquid CDx.
Mata DA, Kou AA, Heilmann AM, et al. · J Mol Diagn · 2025
- Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA, Lee JK, Shanmugam V, et al. · Histopathology · 2024
- Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Napolitano S, De Falco V, Martini G, et al. · JAMA Oncol · 2023Clinical Trial, Phase II, Randomized Controlled Trial
- Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Chibaudel B, Carola E, Mekranter H, et al. · Int J Mol Sci · 2025
- Detection of a Rare Intra-ALK Inversion and ALK Rearrangement in a Lung Adenocarcinoma Patient by FoundationOne Liquid CDx and Successful Treatment with Alectinib: Case Report.
Kanno C, Takahashi S, Hagiwara M, et al. · JTO Clin Res Rep · 2026Case Reports
- Prognostic Impact of Blood Tumor Mutational Burden in pMMR/MSS Metastatic Colorectal Cancer Assessed by FoundationOne® Liquid CDx.
Chibaudel B, Carola E, Mekranter H, et al. · Cancers (Basel) · 2026
- The diagnostic accuracy of next-generation sequencing in advanced NSCLC.
Ko EY, Wong JWH, Shih DJH, et al. · J Liq Biopsy · 2025
- Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine.
Ballatore Z, Bozzi F, Cardea S, et al. · J Clin Med · 2023
Other devices of this type
Also filed under product code PQP.
- FoundationOne CDxFoundation Medicine, Inc. · PMA 2026
- Oncomine Dx Target TestLife Technologies Corporation · PMA 2025
- Guardant360 CDxGuardant Health, Inc. · PMA 2026
- Oncomine Dx Express TestLife Technologies Corporation · PMA 2026
- xT CDxTempus AI, Inc. · PMA 2026
- TruSight Oncology ComprehensiveIllumina, Inc. · PMA 2026
- FoundationOne®Liquid CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOneCDx (F1CDx)Foundation Medicine, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.